Today: 29 April 2026
AppLovin stock price slips after hours as CloudX launch and Wedbush target cut put Feb. 11 earnings in play
6 February 2026
2 mins read

AppLovin stock price slips after hours as CloudX launch and Wedbush target cut put Feb. 11 earnings in play

New York, Feb 5, 2026, 17:59 ET — After-hours

  • AppLovin shares edged lower in late trading after another volatile session for the ad-tech stock.
  • A Wedbush analyst cut his price target, pointing to a valuation reset and headwinds.
  • Investors are bracing for Feb. 11 results as talk of AI-driven competition swirls.

AppLovin shares fell 3.1% to $375.23 in after-hours trading on Thursday, after swinging between $360.13 and $401.10 earlier in the session.

The move lands with the stock already on a short fuse. A broad selloff has hit software and services names as investors debate whether new AI tools will start eating into established business models, wiping about $830 billion in market value from the group since late January, Reuters reported.

Wall Street’s tone did not help on Thursday. The Nasdaq ended sharply lower as investors fretted over a fresh wave of heavy AI spending and whether it will translate into profits, Reuters said, with SimCorp’s Melissa Brown calling last year’s “AI trade” an “extinguisher” this year. Reuters

On the AppLovin-specific side, Wedbush analyst Michael Pachter cut his price target on the stock to $465 from $800 while keeping an Outperform rating, citing a reset in valuation amid softer industry sentiment and potential headwinds. Wedbush said AppLovin’s push into e-commerce and, eventually, connected TV could help offset competitive pressure, but flagged regulatory issues and weaker e-commerce data from rivals as reasons to re-rate the stock.

Competition jitters have also grown louder this week after industry publication AdExchanger reported that CloudX, a mobile-ad platform, launched into “general availability” on Wednesday — meaning the product is now broadly available. AdExchanger said CloudX is using large language model agents, or AI systems trained on vast text data, to automate ad-operations tasks, quoting CEO Jim Payne: “There’s a limit to what a single ad monetization person can do.” AdExchanger

CloudX, on its website, said it is now generally available with seven bidders — Meta, Unity, Liftoff, Magnite, InMobi, Mintegral and Moloco — competing in the same auction, and it highlighted early partnerships with publishers including Scopely and 52 Entertainment.

AppLovin’s slide accelerated a day earlier. The stock dropped 16.1% on Wednesday to around $387 on heavy volume, after trading as low as $382.40, MarketBeat reported.

The selling has not looked like a routine tech dip. In the software sector more broadly, dip-buyers have been “not as eager” and options flows have stayed “overwhelmingly defensive,” Reuters reported, citing Interactive Brokers strategist Steve Sosnick and Susquehanna’s Chris Murphy. Reuters

Next week brings a hard catalyst. AppLovin said it will report fourth-quarter and full-year 2025 results on Feb. 11 after the U.S. market closes and host a webcast at 5 p.m. ET, led by CEO Adam Foroughi and CFO Matthew Stumpf.

But the stock’s whipsaw cuts both ways. A Pomerantz law firm notice this week said it is investigating claims on behalf of AppLovin investors, citing a CapitalWatch report that alleged the company was tied to illicit funds — the sort of headline risk that can keep some funds on the sidelines even as others hunt for a bottom.

For now, traders head into Friday watching for any easing in the software selloff and for follow-through on CloudX headlines. The bigger test comes after the bell on Feb. 11, when AppLovin’s results and guidance will show whether its ad engine can keep delivering through a fast-shifting market.

Stock Market Today

  • Sensex Rallies 609 Points as Nifty Nears 24,200 on Strong Earnings and Geopolitical Hope
    April 29, 2026, 9:39 AM EDT. Indian benchmark indices rebounded Wednesday with the BSE Sensex rising 609 points (0.79%) to 77,496.36 and the NSE Nifty climbing 182 points (0.76%) to 24,177.65. Gains were broad-based, led by FMCG, auto, and telecom stocks. Maruti Suzuki surged nearly 3% following a record annual net profit, lifted by highest-ever sales and GST rate cuts. Positive earnings reports and easing geopolitical tensions fueled investor sentiment despite elevated crude oil prices which rose 2.85% to $114.4 a barrel. Asian markets also closed higher, reflecting a global mood shift. However, European and U.S. markets remained subdued. Analysts noted improved corporate performance and hopes of reduced global conflicts helped offset macroeconomic concerns and contributed to today's rebound.

Latest article

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

29 April 2026
Biogen lowered its 2026 adjusted earnings forecast to $14.25–$15.25 per share, citing research and development charges from recent acquisitions. First-quarter revenue rose 2% to $2.48 billion, with adjusted earnings of $3.57 per share, beating analyst estimates. Leqembi sales climbed 74% to $168 million globally.
Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Qualcomm stock price slides after-hours on weak outlook as memory crunch squeezes phones
Previous Story

Qualcomm stock price slides after-hours on weak outlook as memory crunch squeezes phones

S&P Global stock (SPGI) slides after hours as investors brace for earnings, Mobility spin-off updates
Next Story

S&P Global stock (SPGI) slides after hours as investors brace for earnings, Mobility spin-off updates

Go toTop